A recent approved drug for axial spondyloarthritis, bimekizumab, a monoclonal antibody that selectively inhibits IL-17A and IL-17F, has showed a lower incidence rate of uveitis among patients randomized to this drug in a pooled analysis from phase 2b/3 trials (14). This evidence concerns the gene IL17A and uveitis.